transmembrane protein 35AGenealiases: NACHO · TMEM35 · TUF-1
Q-omics provides the consensus-scored TMEM35A profile across patient tissues and cancer cell-line models. TMEM35A expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, TMEM35A is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, TMEM35A RNA expression shows 15,445 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, BLCA, and TGCT as cancer lineages where TMEM35A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM35A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM35A survival associations across molecular data types. TMEM35A RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM35A RNA expression–survival associations across cancer types. High TMEM35A expression shows unfavorable associations in THCA, but favorable associations in OV, UCEC, HNSC, LGG and KIRC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for TMEM35A RNA expression.
This table summarizes TMEM35A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM35A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM35A shows lower tumor expression in BLCA, COAD, KIRP, THCA, STAD and LUSC. The BLCA box plot shows higher TMEM35A RNA expression in normal versus tumor tissue (log2 FC = −4.882, t-test p < 0.001).
This table shows molecular features associated with TMEM35A in patient tissues and cancer cell lines. In patient samples, TMEM35A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM35A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and KIDNEY.
